Pilot study of the combination of melphalan, carboplatin and etoposide as a conditioning regimen for relapsed lymphoma patients

Acta Haematologica

Volumn 102, Issue 1, 1999, Pages 56-58

  Del Giglio, Auro ^a   Costa, L J M ^b   Pinczowski, H ^a   Varella, P C S ^a   Luzzi, J R ^a,c   Neves, P ^c   Mota, A ^a   Boente, P ^d   Sampaio, C ^d  

^a FACULDADE DE MEDICINA DO ABC   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c Samaritan Hospital Blood Bank   (Brazil)

^d GEPAGRI/CCA/UPSCar   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; ETOPOSIDE; MELPHALAN;

ADOLESCENT; ADULT; ARTICLE; BONE MARROW TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CLINICAL ARTICLE; CLINICAL TRIAL; HUMAN; LYMPHOMA; PRIORITY JOURNAL;

ADOLESCENT; ADULT; ANTINEOPLASTIC AGENTS; CARBOPLATIN; COMBINED MODALITY THERAPY; ETOPOSIDE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HODGKIN DISEASE; HUMANS; LYMPHOMA, NON-HODGKIN; MELPHALAN; MIDDLE AGED; PILOT PROJECTS; RECURRENCE; TRANSPLANTATION CONDITIONING;

EID: 0032842636     PISSN: 00015792     EISSN: None     Source Type: Journal    
DOI: 10.1159/000040969     Document Type: Article

References (13)

1. Rodriguez MA, Cabanillas FC, Velasquez W, Hagemeister FB, McLaughlin P, Swan F, Romaguera JE: Results of a Salvage Treatment Program for Relapsing Lymphoma: MINE Consolidated with ESHAP. J Clin Oncol 1995; 13:1734-1741.
2. Vose JM, Anderson JR, Kessinger A, Bierman PJ, Coccia P, Reed EC, Gordon B, Armitage JO: High-dose chemotherapy and autologous hematopoietic stem-cell transplantation for aggressive non-Hodgkin's lymphoma. J Clin Oncol 1993;11:1846-1851.
3. van Besien K, Tabocoff J, Rodriguez M, Andersson B, Mehra R, Przepiorka D, Dimopoulos M, Giralt S, Suki S, Khouri I, Spitzer G, Jagannath S, Dicke K, Le Maistre CF, Deisseroth A, Cabanillas F, Champlin RE: High-dose chemotherapy with BEAC regimen and autologous bone marrow transplantation for intermediate grade and immunoblastic lymphoma: Durable complete remissions, but a high rate of regimen-related toxicity. Bone Marrow Transplant 1995;15:549-555.
4. Weaver CH, Schwartzberg L, Zhen B, Mangum M, Leff R, Tauer K, Rosenberg A, Pendergrass K, Kaywin P, Hainsworth J, Greco FA, West WH, Buckner CD: High-dose chemotherapy and peripheral blood stem cell infusion in patients with non-Hodgkin's lymphoma: Results of outpatient treatment in community cancer centers. Bone Marrow Transplant 1997;20: 753-760.
5. Philip T, Guglielmi C, Hagenbeek A, Somers R, Van der Lelie H, Bron D, Sonneveld P, Gisselbrecht C, Cahn JY, Harousseau JL, Coiffier B, Biron P, Mandelli F, Chauvin F: Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995;333:1540-1545
6. Velasquez WS, Cabanillas F, Salvador P, McLaughlin P, Fridrik M, Tucker S, Jagannath S, Hagemeister FB, Redman JR, Swan F, Barlogie B: Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP). Blood 1988;71:117-122.
7. Lidor YJ, Shpall EJ, Peters WP, Bast RC Jr: Synergistic cytotoxicity of different alkylating agents for epithelial ovarian cancer. Int J Cancer 1991;49:704-710.
8. Roed H, Vindelov LL, Christensen IJ, Spang-Thomsen M, Hansen HH: The cytotoxic of cisplatin, carboplatin and teniposide alone and combined determined on four human small cell lung cancer cell lines by the clonogenic assay. Eur J Cancer Clin Oncol 1988;24:247-253.
9. Hempel L, Kremens B, Weirich A, Graf N, Zintl F, Ludwig R: High-dose consolidation with autologous stem cell rescue (ASCR) for nephroblastoma initially treated according to the SIOP 9/GPOH trial and study. Klin Pädiatr 1996;208:186-189.
10. Benedetti Panici P, Pierelli L, Scambia G, Foddai ML, Salerno MG, Menichella G, Vittori M, Maneschi F, Caracussi U, Serafini R, Leone G, Mancuso S: High-dose carboplatin, etoposide and melphalan (CEM) with peripheral blood progenitor cell support as late intensification for high-risk cancer: Non-haematological, haematological toxicities and role of growth factor administration. Br J Cancer 1997;75:1205-1212.
11. Kupari M, Volin L, Suokas A, Timonen T, Hekali P, Ruutu T: Cardiac involvement in bone marrow transplantation: Electrocardiographic changes, arrhythmias, heart failure and autopsy findings. Bone Marrow Transplant 1990;5:91-98.
12. Hess AD, Jones RC, Santos GW: Autologous graft-vs-host disease: Mechanisms and potential therapeutic effect. Bone Marrow Transplant 1993;12(suppl3):S65-S69.
13. Horn TD: Acute cutaneous eruptions after marrow ablation: Roses by other names? J Cutan Pathol 1994;21:385-392.